Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2018, Article ID 8432781, 9 pages
https://doi.org/10.1155/2018/8432781
Review Article

Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis

1Department of Medicine, West Virginia University Hospitals, Morgantown, WV, USA
2Department of Medicine, Section of Digestive Diseases, West Virginia University Hospitals, Morgantown, WV, USA
3Department of Medicine, Section of Hematology, West Virginia University Hospitals, Morgantown, WV, USA

Correspondence should be addressed to P. Priyanka; ude.uvw.csh@aknayirp.aknayirp

Received 6 April 2018; Accepted 30 April 2018; Published 5 June 2018

Academic Editor: Dirk Uhlmann

Copyright © 2018 P. Priyanka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Amitrano, M. A. Guardascione, V. Brancaccio et al., “Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis,” Journal of Hepatology, vol. 40, no. 5, pp. 736–741, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. X. Qi, V. de Stefano, H. Li, J. Dai, X. Guo, and D. Fan, “Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies,” European Journal of Internal Medicine, vol. 26, no. 1, pp. 23–29, 2015. View at Publisher · View at Google Scholar
  3. L. Loffredo, D. Pastori, A. Farcomeni, and F. Violi, “Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis,” Gastroenterology, vol. 153, no. 2, pp. 480–487.e1, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Chen, F. Turon, V. Hernández-Gea et al., “Nontumoral portal vein thrombosis in patients awaiting liver transplantation,” Liver Transplantation, vol. 22, no. 3, pp. 352–365, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. M. G. Delgado, S. Seijo, and I. Yepes, “Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis,” Clinical Gastroenterology and Hepatology, vol. 10, no. 7, pp. 776–783, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Senzolo, T. M. Sartori, V. Rossetto et al., “Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis,” Liver International, vol. 32, no. 6, pp. 919–927, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Villa, C. Cammà, M. Marietta et al., “Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis,” Gastroenterology, vol. 143, no. 5, pp. 1253–1260, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. N. M. Intagliata, Z. H. Henry, H. Maitland et al., “Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation,” Digestive Diseases and Sciences, vol. 61, no. 6, pp. 1721–1727, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Hum, J. J. Shatzel, J. H. Jou, and T. G. Deloughery, “The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis,” European Journal of Haematology, vol. 98, no. 4, pp. 393–397, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. A. De Gottardi, J. Trebicka, C. Klinger et al., “Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis,” Liver International, vol. 37, no. 5, pp. 694–699, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Lenz, B. Dieplinger, R. Buder, P. Piringer, M. Rauch, and M. Voglmayr, “Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban,” Zeitschrift für Gastroenterologie, vol. 52, no. 10, pp. 1175–1177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Yang, S. R. Kim, and M. J. Song, “Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban,” Clinical and Molecular Hepatology, vol. 22, no. 4, pp. 499–502, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. L. D. DeLeve, D.-C. Valla, and G. Garcia-Tsao, “Vascular disorders of the liver,” Hepatology, vol. 49, no. 5, pp. 1729–1764, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Condat, F. Pessione, S. Hillaire et al., “Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy,” Gastroenterology, vol. 120, no. 2, pp. 490–497, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Ageno, N. Riva, S. Schulman et al., “Long-term clinical outcomes of splanchnic vein thrombosis results of an international registry,” JAMA Internal Medicine, vol. 175, no. 9, pp. 1474–1480, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Ageno, A. S. Gallus, A. Wittkowsky, M. Crowther, E. M. Hylek, and G. Palareti, “Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” CHEST, vol. 141, no. 2, supplement, pp. e44S–e88S, 2012. View at Publisher · View at Google Scholar
  17. K. I. Rodríguez-Castro, R. J. Porte, E. Nadal, G. Germani, P. Burra, and M. Senzolo, “Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review,” Transplantation, vol. 94, no. 11, pp. 1145–1153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Seijo and J. C. Garcia-Pagan, “Anticoagulation in cirrhosis: Ready ... set ... wait!,” Hepatology, vol. 58, no. 3, pp. 1175-1176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. D. T. Janczak, M. K. Mimier, R. D. McBane et al., “Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location,” Mayo Clinic Proceedings, vol. 93, no. 1, pp. 40–47, 2018. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Qi, E. M. Yoshida, N. Mendez-Sanchez, and X. Guo, “Rivaroxaban recanalized occlusive superior mesenteric vein thrombosis, but increased the risk of bleeding in a cirrhotic patient,” Liver International, vol. 37, no. 10, pp. 1574-1575, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Nery, D. Valadares, S. Morais, M. T. Gomes, and A. De Gottardi, “Efficacy and Safety of Direct-Acting Oral Anticoagulants Use in Acute Portal Vein Thrombosis Unrelated to Cirrhosis,” Gastroenterology Research, vol. 10, no. 2, pp. 141–143, 2017. View at Publisher · View at Google Scholar
  22. M. Martinez, A. Tandra, and R. Vuppalanchi, “Treatment of acute portal vein thrombosis by nontraditional anticoagulation,” Hepatology, vol. 60, no. 1, pp. 425-426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Pannach, J. Babatz, and J. Beyer-Westendorf, “Successful treatment of acute portal vein thrombosis with rivaroxaban,” Thrombosis and Haemostasis, vol. 110, no. 4, pp. 626-627, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Potze, F. Arshad, J. Adelmeijer et al., “Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis,” British Journal of Haematology, vol. 163, no. 5, pp. 666–673, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. A. Smythe, J. Fanikos, M. P. Gulseth et al., “Rivaroxaban: Practical considerations for ensuring safety and efficacy,” Pharmacotherapy, vol. 33, no. 11, pp. 1223–1245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Morrill, D. Ge, and K. C. Willett, “Dosing of Target-Specific Oral Anticoagulants in Special Populations,” Annals of Pharmacotherapy, vol. 49, no. 9, pp. 1031–1045, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. S. M. Bates and J. S. Ginsberg, “Clinical practice. Treatment of deep-vein thrombosis,” The New England Journal of Medicine, vol. 351, no. 3, pp. 268–277, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Liakoni, A. E. Rätz Bravo, and S. Krähenbühl, “Hepatotoxicity of New Oral Anticoagulants (NOACs),” Drug Safety, vol. 38, no. 8, pp. 711–720, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Caldeira, M. Barra, A. T. Santos et al., “Risk of drug-induced liver injury with the new oral anticoagulants: Systematic review and meta-analysis,” Heart, vol. 100, no. 7, pp. 550–556, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Graff and S. Harder, “Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment,” Clinical Pharmacokinetics, vol. 52, no. 4, pp. 243–254, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Potze, J. Adelmeijer, and T. Lisman, “Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis,” Hepatology, vol. 61, no. 4, pp. 1435-1436, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Zocco, E. di Stasio, R. de Cristofaro et al., “Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development,” Journal of Hepatology, vol. 51, no. 4, pp. 682–689, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. Xarelto (rivaroxaban) [package insert], Janssen Pharmaceuticals Inc. Titusville, http://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf.
  34. Eliquis(apixaban) [package insert], Bristol-Myers Squibb, New York, NY, USA, http://packageinserts.bms.com/pi/pi_eliquis.pdf.
  35. Savaysa (edoxaban) [package insert], Daiichi Sankyo, Tokyo, Japan, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
  36. T. A. Dewald and R. C. Becker, “The pharmacology of novel oral anticoagulants,” Journal of Thrombosis and Thrombolysis, vol. 37, no. 2, pp. 217–233, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. D. A. Parasrampuria, T. Kanamaru, A. Connor et al., “Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule,” Clinical Pharmacology and Therapeutics, vol. 55, no. 11, pp. 1286–1292, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. Pradaxa (dabigatran) [package insert], Boehringer Ingelheim Pharmaceuticals, Inc, 2015.
  39. J. van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis & Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Stangier, B. I. Eriksson, O. E. Dahl et al., “Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement,” Clinical Pharmacology and Therapeutics, vol. 45, no. 5, pp. 555–563, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Tran, J. Joseph, L. Young et al., “New oral anticoagulants: A practical guide on prescription, laboratory testing and peri-procedural/bleeding management,” Internal Medicine Journal, vol. 44, no. 6, pp. 525–536, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. J. W. Eikelboom, D. J. Quinlan, J. Hirsh, S. J. Connolly, and J. I. Weitz, “Laboratory monitoring of non-Vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: A review,” JAMA Cardiology, vol. 2, no. 5, pp. 566–574, 2017. View at Publisher · View at Google Scholar · View at Scopus
  44. I. L. Holster, V. E. Valkhoff, E. J. Kuipers, and E. T. T. L. Tjwa, “New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis,” Gastroenterology, vol. 145, no. 1, pp. 105.e15–112.e15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Francoz, J. Belghiti, V. Vilgrain et al., “Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation,” Gut, vol. 54, no. 5, pp. 691–697, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Amitrano, M. A. Guardascione, A. Menchise et al., “Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis,” Journal of Clinical Gastroenterology, vol. 44, no. 6, pp. 448–451, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. C. D. Seaman, K. J. Smith, and M. V. Ragni, “Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: A U.S. perspective,” Thrombosis Research, vol. 132, no. 6, pp. 647–651, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Kubitza, A. Roth, M. Becka et al., “Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban—an oral, direct Factor Xa inhibitor,” British Journal of Clinical Pharmacology, vol. 76, no. 1, pp. 89–98, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Mendell, L. Johnson, and S. Chen, “An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics,” Clinical Pharmacology and Therapeutics, vol. 55, no. 12, pp. 1395–1405, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Tornkvist, J. G. Smith, and A. Labaf, “Current evidence of oral anticoagulant reversal: A systematic review,” Thrombosis Research, vol. 162, pp. 22–31, 2018. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Y. Hu, V. R. Vaidya, and S. J. Asirvatham, “Reversing anticoagulant effects of novel oral anticoagulants: Role of ciraparantag, andexanetalfa, and idarucizumab,” Vascular Health and Risk Management, vol. 12, pp. 35–44, 2016. View at Publisher · View at Google Scholar · View at Scopus